Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLX925 in relapsed or refractory AML
NCT02335814Phase 1Terminated
- Sponsor
- RAPT Therapeutics
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMG 925 in acute myeloid leukemia (AML), sponsored by RAPT Therapeutics. Primary endpoints: Incidence of adverse events at 30 Months, Maximum Tolerated Dose and Recommended Phase 2 Dose at 12 Months and 1 more. Started Apr 2015; status: terminated.
02
Drugs
AMG 925
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02335814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335814.